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Dr. Ignatio Witsuba (MD Anderson) started this sessionby giving an overview of the fibroblast growth factor
(FGF) pathway and expression of FGFs (22 members), FGF
receptors (FGFRs, four members), and their gene family
members in non-small cell lung cancer (NSCLC). FGF-
FGFR interaction plays crucial role in normal development,
and deregulation of their signaling is associated with carci-
nogenesis. Overexpression of FGFRs (1 and 2) and FGFs
(e.g., 2, 7, and 9) has been reported in 50 to 80% of squamous
cell carcinoma and adenocarcinoma. Mutations and amplifi-
cation of FGFR-1, -2, and -4 have also been noted in NSCLC.
Moreover, isoforms arising from alternative splicing of these
FGFRs may be differentially expressed in various subtypes of
NSCLC. Dr. Paul Bunn (Colorado) followed by discussing
the novel hypothesis that expression of FGFR 2 and 3 may be
transcriptionally activated when NSCLC cells are treated by
epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR TKI), leading to activation of EGFR downstream
signaling (ERK) and possibly resistance to EGFR TKI. Dr.
Bunn presented preliminary data showing that a genome wide
short hairpins(sh) RNA experiment identified FGFR as a
synthetic lethal gene with EGFR TKI therapy, i.e., inhibition
of FGFR (e.g., by AZ12908010) may enhance EGFR TKI
activity. Dr. Sbar (Bristol-Myer Squibb) reported next the
development of Brivanib, a dual vascular endothelial
growth factor receptor and FGFR inhibitor in NSCLC. The
IC50 of Brivanib for FGFR-1, -2, and -3 is between 60 and
150 nM, and it inhibits proliferation in vitro and angio-
genesis in vivo in the L2987 lung cancer cell line model.
FGFR signaling may also cause resistance to anti-vascular
endothelial growth factor therapy. Result of phase 2 study
has reported significant response to Brivanib  erlotinib in
patients with heavily pretreated advanced KRAS wild-type
colorectal cancer. A double-blinded/randomized with-
drawal phase 2 study is being planned for patients with
advanced stage treatment refractory NSCLC. Dr. David
Spiegel (Vanderbilt) next discussed the FGFR monoclonal
antibodies that are being developed for cancer therapy.
These include AV-370 (anti-FGFR3) and FP-1039 (FGF
trap) with limited in vitro cell line and in vivo results. He
concluded that these novel biologics are still in their early
phase development. The session concluded by discussion
of the EPH/Ephrins especially EphB4 by Dr. Ravi Salgia
(Chicago). Ephrins (ligand) and their receptors (Eph re-
ceptors) play important role in normal embryonic devel-
opmental processes such as vasculogenesis, cell migration,
tissue-border formation, and axonal/synaptic network de-
velopment. In tumors, they may promote cell proliferation,
motility, invasion, metastasis, and angiogenesis. The ex-
pression of EpHA (nine members in human) and EphB (five
members in human) are commonly induced in human malignan-
cies. EphB4 overexpression has been reported in adeno and
squamous carcinoma of the lung. Potential inhibitors include
soluble inhibitor, monoclonal antibody, and small molecule
inhibitors, although none of the latter has entered clinical study.
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